文献速递前列腺增生与排尿功能障碍

铥光纤激光与钬激光MOSES技术在良性前列腺增生剜除术中的随机对照研究

Thulium fiber laser versus holmium MOSESTM laser enucleation of the prostate for the treatment of benign prostatic hyperplasia: a randomized prospective clinical study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-07-08

这项随机前瞻性临床研究比较了钬激光剜除术(M-HoLEP,采用MOSESTM技术)与铥光纤激光剜除术(ThuFLEP)治疗良性前列腺增生(BPH)的围手术期及术后1年结局。共纳入104例患者,每组52例。结果显示M-HoLEP在剜除时间、剜除效率、持续膀胱冲洗时间、血尿程度、术后血尿持续时间、导尿管留置时间和住院时间方面均优于ThuFLEP,且ThuFLEP组术后即刻血尿入院率显著更高(30.8% vs 7.7%,p=0.003)。两组术后12个月内的功能结局相当。

要点

  • M-HoLEP剜除时间更短(50 vs 57.5分钟,p<0.001),剜除效率更高(1.97 vs 1.49 g/min,p<0.001)。
  • M-HoLEP组术后即刻血尿入院率显著低于ThuFLEP组(7.7% vs 30.8%,p=0.003)。
  • M-HoLEP在膀胱冲洗时间、血尿程度、导尿管留置时间和住院时间上均更优,支持当日出院尝试排尿。

核心结论

  • 铥光纤激光和MOSESTM技术在前列腺内镜剜除术中均能获得满意的术中及术后功能结局。
  • MOSESTM技术在剜除时间、剜除效率、导尿管留置时间和住院时间方面表现更优。
  • M-HoLEP有助于实现当日出院尝试排尿并减少术后住院。

研究设计与样本

  • 随机前瞻性临床研究,纳入2022年6月至2024年1月期间接受M-HoLEP或ThuFLEP的104例BPH患者,每组52例。
  • 评估术前及前列腺数据,分析术中数据和围手术期结局,随访12个月。

主要发现

  • 两组术前特征无统计学显著差异。
  • M-HoLEP中位剜除时间更短(50 vs 57.5分钟,p<0.001),剜除效率更高(1.97 vs 1.49 g/min,p<0.001)。
  • M-HoLEP在持续膀胱冲洗时间、血尿程度、术后血尿持续时间、导尿管留置时间和住院时间方面均显著更优。
  • ThuFLEP组约30.8%患者因术后即刻血尿入院,M-HoLEP组为7.7%(p=0.003)。
  • 两组术后12个月内的结局相当。

关键数值与推荐

  • M-HoLEP中位剜除时间50分钟 vs ThuFLEP 57.5分钟,p<0.001。
  • M-HoLEP剜除效率1.97 g/min vs ThuFLEP 1.49 g/min,p<0.001。
  • 术后即刻血尿入院率:ThuFLEP组30.8% vs M-HoLEP组7.7%,p=0.003。

临床怎么用

  • 在BPH内镜剜除术中,M-HoLEP可缩短剜除时间和导尿管留置时间,提高剜除效率。
  • M-HoLEP降低术后即刻血尿入院率,支持当日出院尝试排尿,减少住院。
  • 两种技术术后12个月功能结局相当,选择可基于设备可用性和术者偏好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to compare intraoperative and one-year postoperative outcomes of patients treated for benign prostatic hyperplasia (BPH) with holmium laser enucleation of the prostate using MOSESTM technology (M-HoLEP) and thulium fiber laser enucleation of the prostate (ThuFLEP). METHODS: We included 104 patients who underwent M-HoLEP or ThuFLEP between June 2022 and January 2024 in this randomized controlled trial. Patients' preoperative and prostate data were evaluated. Intraoperative data and perioperative outcomes were analyzed over the 12-month follow-up period. RESULTS: Fifty-two patients underwent M-HoLEP, and 52 were managed with ThuFLEP. There were no statistically significant differences in the preoperative characteristics between the groups. M-HoLEP had a shorter median enucleation time (50 vs. 57.5 minutes, p < 0.001) and demonstrated significantly higher enucleation efficiency than ThuFLEP (1.97 vs. 1.49 g/min, p < 0.001). Significant differences were observed favoring M-HoLEP regarding continuous bladder irrigation time, hematuria scale, duration of postoperative hematuria, catheterization time, and hospital stay. Approximately 30.8% of ThuFLEP patients were admitted with immediate postoperative hematuria versus 7.7% in the M-HoLEP group, p = 0.003). The postoperative outcomes were comparable between the cohorts up to 12 months. CONCLUSIONS: Thulium fiber laser (TFL) and MOSESTM technology achieved satisfactory intraoperative and postoperative functional outcomes in endoscopic enucleation of the prostate. However, MOSESTM technology demonstrated superior results in terms of enucleation time and efficiency, catheterization time, and hospital stay. M-HoLEP facilitates same-day trial-of-void and reduces postoperative hospital admissions.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Elmansy H, Alhelal S, Blahitko O, et al. Thulium fiber laser versus holmium MOSESTM laser enucleation of the prostate for the treatment of benign prostatic hyperplasia: a randomized prospective clinical study. Prostate Cancer Prostatic Dis. 2025. PMID: 40624120. doi:10.1038/s41391-025-00996-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。